MEGAN EDWARDS: Open Payments
NPI 1427674654 · LAKEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,186 in 85 payments from 18 companies in 2025. Trend: 2023 $1,531 · 2024 $1,939 · 2025 $2,186
Food & beverage: $2,186
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 20 | $822 |
| ViiV Healthcare Company | 18 | $509 |
| ABBVIE INC. | 20 | $327 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $61 |
| Lilly USA, LLC | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Novo Nordisk Inc | 1 | $29 |
| Merck Sharp & Dohme LLC | 1 | $28 |
Products named: DOVATO, VRAYLAR, APRETUDE, QULIPTA, REXULTI, Biktarvy, CAPLYTA, CABENUVA.
Industry payments across CO — which companies pay providers there.
